Article
Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis.
European review for medical and pharmacological sciences - 1 Oct 2021
Lee H J, Jeong G H, Li H, Kim M S, Kim J S, Park S J, Han Y J, Lee K H, Kronbichler A, Hong S H, Ghayda R A, Luchini C, Nottegar A, Koyanagi A, Smith L, Jacob L, Dragioti E, Radua J, Cargnin S, Terrazzino S, Thompson T, Yon D K, Lee S W, Yang J M, Wasuwanich P, Shin J I, Gamerith G
Abstract excerpt
OBJECTIVE: It is controversial whether there is efficacy or safety benefit of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in advanced EGFR-mutated non-small cell lung cancer (NSCLC) compared to standard chemotherapy. We aim to assess the efficacy and safety of EGFR-TKIs compared to other chemotherapeutics in EGFR-mutated NSCLC. MATERIALS AND METHODS: Up to April 27th, 2020, PubMed,...
Topics
Join the communities discussing this publication.